Radiation zaps prostate cancer spots in men not helped enough by hormone drugs

NCT ID NCT07644754

Not yet recruiting Disease control Sponsor: University Hospital Tuebingen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving radiotherapy to the prostate and to cancer spots seen on PET scans can help men with metastatic prostate cancer whose PSA levels remain high after six months of hormone therapy. Participants continue their hormone treatment and receive three PSMA-PET scans along with targeted radiation. The main goal is to see if the cancer stops growing on imaging one year after radiotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiotherapy
What this could lead to: If successful, this approach could offer a way to better control metastatic prostate cancer by targeting both the primary tumor and remaining cancer spots with radiation.
What could go wrong: This is a small, early-phase study with only 27 participants, so results may not apply to all patients. Radiotherapy can cause side effects like fatigue or local irritation, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER PROSTATE CANCER METASTATIC DISEASE PROSTATE CANCER METASTATIC TO BONE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.